Kamada announces plans to price initial public sale of ordinary stock

Offering's proceeds used for clinical trials, research and development

By Devika Patel

Knoxville, Tenn., April 11 - Kamada Ltd. will price an initial public offering of its ordinary stock, according to a Form S-1 filed Thursday with the Securities and Exchange Commission. The company expects its shares will trade on the Nasdaq under the symbol "KMDA."

The deal will have a greenshoe option.

Morgan Stanley & Co. LLC and Jefferies LLC are assisting.

Proceeds will be used for clinical trials, research and development for additional AAT indications, expanding distribution capabilities, expanding manufacturing infrastructure and general corporate purposes.

The orphan drug-focused, plasma-derived protein therapeutics company is based in Ness Ziona, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.